The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 09, 2025

Filed:

Feb. 24, 2022
Applicant:

Actinium Pharmaceuticals, Inc., New York, NY (US);

Inventor:

Dragan Cicic, Brooklyn, NY (US);

Assignee:

Actinium Phamaceuticals, Inc., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 51/10 (2006.01); A61P 35/02 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 51/1069 (2013.01); A61K 51/1093 (2013.01); A61K 51/1096 (2013.01); A61P 35/02 (2018.01); A61K 2039/505 (2013.01);
Abstract

This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such asAc-HuM195.


Find Patent Forward Citations

Loading…